CETP and inflammatory bowel disease: Pharmacological inhibitors of CETP exist, from the perspective of clinical translation, contemporary CETPi are attractive in that they increase HDL-C via a mechanism relevant to the metabolic changes that occur during IBD, and have been shown to be safe and well tolerated in large clinical trials of patients with CVD after several generation development, although torcetrapib (first generation drug of CETPi) was associated with increased risk of mortality from infection in humans (30, 31, 32, 33).